alitretinoin (panretin) Report issue

Small molecule Orphan Drug FDA Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Alitretinoin, or 9-cis-retinoic acid, is a form of vitamin A. It is also used in medicine as an antineoplastic (anti-cancer) agent developed by Ligand Pharmaceuticals. Alitretinoin (9-cis-retinoic acid) is a naturally-occurring endogenous retinoid indicated for topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma. Alitretinoin inhibits the growth of Kaposi's sarcoma (KS) cells in vitro. Alitretinoin binds to and activates all known intracellular retinoid receptor subtypes (RARa, RARb, RARg, RXRa, RXRb and RXRg). Once activated these receptors function as transcription factors that regulate the expression of genes that control the process of cellular differentiation and proliferation in both normal and neoplastic cells. In the United States, topical alitretinoin (in the form of a gel; trade name Panretin) is indicated for the treatment of skin lesions in AIDS-related Kaposi's sarcoma.   NCATS

Chemistry

  • SMILES: CC(\C=C\C1=C(C)CCCC1(C)C)=C\C=C\C(C)=C\C(O)=O
  • InChIKey: SHGAZHPCJJPHSC-ZVCIMWCZSA-N
  • Mol. Mass: 300.4351
  • ALogP: 5.6
  • ChEMBL Molecule:
    alitretinoin  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$65.8118 - $86.5947
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

(2e,4e,6z,8e)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid | 9-cis-retinoic acid | 9-cis-tretinoin | 9cra compound | 9(z)-retinoic acid | agn-192013 | alitretinoin | alitretinoína | alitrétinoïne | alitretinoinum | alrt1057 | alrt-1057 | bal4079 | lg100057 | lg-100057 | lgd1057 | lgd-1057 | panretin | panretyn | panrexin | toctino

Organizations (16)

Research & Development (14)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (11)

Approved Indications (2)


 

Acne Vulgaris (approved 1982)

Sarcoma, Kaposi (approved 1999)

Experimental Indications - Clinical Trial Phases 1-4 (10)


 

Breast Neoplasms (Phase 1)

Dermatitis, Atopic (Phase 4)

Eczema ()

Hand Dermatoses (Phase 3)

Hepatic Insufficiency (Phase 1/Phase 2)

HIV Infections (Phase 2)

Lichen Planus (Phase 2)

Lupus Erythematosus, Cutaneous (Phase 2)

Psoriasis (Phase 2)

Sarcoma, Kaposi (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 16
  • # of Trial Organizations: 14

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue